Pre-market Hot Trades in US Stocks
Nebius is up 3.31% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 31, Nebius announced plans to build a 310 MW artificial intelligence data center in Lappeenranta, Finland. This project will become one of the largest data centers in Europe, expected to be operational by 2027. This expansion plan has driven the stock price up. Source: MT Newswires
</li>
<li>
On March 31, Nebius signed supply contracts worth over $40 billion with Microsoft and Meta, demonstrating strong demand for its AI capabilities and further solidifying its position in the rapidly growing AI infrastructure market. Source: Reuters
</li>
<li>
On March 31, analysts generally rated Nebius as &#34;Strong Buy,&#34; with an average target price of $166.11, indicating nearly 80% upside potential from current levels. This optimistic analyst rating supports the rise in stock price. Source: TipRanks AI infrastructure demand is strong, with broad market prospects.
</li>
</ol>
Roma Green Finance is down 3.00% in pre-market trading. Based on recent news:
<ol>
<li>
On March 30, Roma Green Finance announced a $100 million stock repurchase plan. This plan will last until December 31, 2028, unless the board modifies, suspends, or terminates it early. The company expects to fund the repurchase from its existing cash balance. This news initially led to a rise in stock price during pre-market trading, but it later fell back.
</li>
<li>
On March 30, Roma Green Finance's stock rose 8.73% in pre-market trading, reaching $6.92 per share. However, market concerns about the long-term impact of the repurchase plan led to a decline in stock price in subsequent trading.
</li>
<li>
On March 31, analysts rated Roma Green Finance as a sell, believing there are five other stocks with better investment value. This rating further undermined investor confidence, leading to a drop in stock price. Market concerns about the long-term impact of the repurchase plan persist.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Hitek Global Inc. is up 146.25% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 27, Hitek Global Inc. announced the sale of 100 million Class A shares to certain institutional investors at a price of $0.03 per share, with the transaction expected to be completed on March 30. This news caused the stock price to surge 146.25% in pre-market trading. Source: MT Newswires
</li>
<li>
On March 27, Hitek Global Inc. announced a $3 million registered direct offering pricing, demonstrating the company's commitment to expanding its business in the technology sector. This move has boosted market confidence in the company's future growth. Source: Hitek Global Inc
On March 27, the company announced in Xiamen the signing of a securities purchase agreement with specific entities, further promoting its business expansion in the information technology consulting and solutions sector. This news boosted investor confidence. Source: Hitek Global Inc.
</li>
</ol>
Apellis Pharma rose 139.96% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 31, Biogen announced its acquisition of Apellis Pharmaceuticals for $5.6 billion. This move aims to expand its treatment capabilities in immunology and rare diseases. The acquisition price of $41 per share is more than double Apellis' closing price on Monday, leading to a significant pre-market surge in Apellis' stock price.
</li>
<li>
On March 31, following the announcement of the acquisition, Apellis' stock price more than doubled in pre-market trading. Biogen will gain two approved drugs through this acquisition, further enhancing its product pipeline.
</li>
<li>
On March 31, Apellis' stock has fallen 32% year-to-date, and this acquisition brings significant market confidence, driving a substantial increase in stock price. The acquisition boosts market confidence, leading to a surge in stock price.
</li>
</ol>
Centessa rose 48.01% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 31, Eli Lilly announced it would acquire Centessa Pharmaceuticals for approximately $6.3 billion to expand its business in the treatment of sleep-wake disorders. This news drove Centessa's stock price up 46% in pre-market trading. Source: Reuters
</li>
<li>
On March 31, Eli Lilly offered a cash bid of $38 per share for this acquisition, along with a non-transferable or contingent value right (CVR) worth approximately $9, bringing the total transaction value to $7.8 billion. This move further enhanced market confidence in Centessa. Source: Bloomberg
</li>
<li>
On March 31, Centessa's CEO Mario Alberto Accardi stated that this acquisition would help drive innovation in the neuroscience field, further enhancing investor optimism about the company's future development. Source: RTTNews The pharmaceutical industry is experiencing active mergers and acquisitions, leading to increased market volatility
</li>
</ol>

NBIS

ROMA

Nebius pre-market up 3.31%; Roma Green Finance pre-market down 3.00%; Hitek Global Inc. pre-market up 146.25%; Apellis Pharma pre-market up 139.96%; Centessa Pharmaceuticals pre-market up 48.01%

Pre-market hot trades in US stocks: Nebius up 3.31% in pre-market; Roma Green Finance down 3.00% in pre-market